Channel Infrastructure NZ Limited
NZRFF News Today: Stay Updated with the Latest Channel Infrastructure NZ Limited News in Real Time
Find NZRFF news now at Meyka AI. Stay informed with the latest Channel Infrastructure NZ Limited stocks updates, including price news, market analysis, and expert insights.
Singapore Telecommunications (Z74.SI) Earnings Preview: EPS at $0.0439 Expected
Z74.SI earnings preview: Singapore Telecommunications reports May 21, 2026. EPS estimate $0.0439, revenue $7.69B. Analyst outlook and key metrics.
Singapore Telecommunications (Z74.SI) Earnings Preview: EPS Seen at $0.0439
Z74.SI earnings preview: Singapore Telecommunications reports May 21, 2026. EPS estimate $0.0439, revenue $7.69B. Dividend yield 3.6%.
Mallorca Drones May 21: Rail Security Tech Battles Vandalism
Mallorca’s SFM railway deploys drone surveillance with thermal imaging and speakers to prevent graffiti vandalism on rail facilities nightly.
KDDL Limited Surges 20% on Strong Earnings Beat, Hits ₹2,614
KDDL.NS stock jumps 20% to ₹2,614 after earnings announcement. Luxury goods maker shows strong momentum on NSE.
SZGPY Maintained at Neutral by Citigroup, May 2026
Citigroup maintains Salzgitter at Neutral with EUR 60 price target raised from EUR 50 on May 20, 2026.
Highlight Event and Entertainment AG Tumbles 9.4% as HLEE.SW Hits Pre-Market Lows
HLEE.SW stock drops 9.4% in pre-market trading on SIX. Entertainment firm faces structural headwinds with negative earnings and weak fundamentals.
Germany Job Crisis May 21: 486K Jobs Lost in Q1 2026
Germany loses 486,000 jobs in Q1 2026. Employment drops to 45.6M as economic crisis deepens. Labor market faces severe headwinds amid weak demand.
Gold Road Resources Limited Trades Near A$3.48 on Strong Dividend Yield
GOR.AX stock trades at A$3.48 with 12.6% dividend yield. Gold Road Resources holds 50% of Gruyere mine with 7.38M oz resources.
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval
SLXN stock jumps 97% after Israeli health ministry approves Phase 2/3 pancreatic cancer trial. Clinical milestone drives biotech rally.